Ottawa Hospital Research Institute

Last updated

The Ottawa Hospital Research Institute (OHRI), formerly Ottawa Health Research Institute, [1] is a non-profit academic health research institute located in the city of Ottawa. It was formed in 2001 following the merger of three Ottawa hospitals. The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and affiliated with the University of Ottawa.

Contents

As of 2022, the Ottawa Hospital Research Institute houses approximately 2,200 scientists, clinician investigators, students, research fellows, and support staff. [2] [3] It has five research programs: Cancer Therapeutics; Chronic Disease; Clinical Epidemiology; Regenerative Medicine; and Neurosciences. [4] Its researchers are studying more than a hundred different diseases, conditions and specialties with an overall focus on translating discoveries and knowledge into better health. [2]

Ronald G. Worton was the research institute's founding CEO and Scientific Director in 2001. [5] In 2007, Duncan Stewart, formerly Chief Cardiologist of St. Michael's Hospital in Toronto and Director of Cardiology of University of Toronto, took over as CEO and Scientific Director. [6] [7]

History

COVID-19

During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1. [8] The candidate is a live replicating virus vaccine using a vaccinia virus vector. [9] Results from pre-clinical studies were published in Molecular Therapy in October 2021. [10] The research team was led by John Bell and was funded by the Thistledown Foundation, Ottawa Hospital Foundation and the Canadian Institutes of Health Research. [11]

Notable discoveries and accomplishments

Notable faculty and alumni

Related Research Articles

<span class="mw-page-title-main">The Ottawa Hospital</span> Hospital in Ontario, Canada

The Ottawa Hospital is a hospital system in Ottawa, Ontario, Canada. The system was formed through the merger of the former Grace Hospital, Ottawa Riverside Hospital, Ottawa General Hospital and Ottawa Civic Hospital. The system is affiliated with the University of Ottawa, and its three campuses are all non-profit, public teaching hospitals.

<span class="mw-page-title-main">Ottawa General Hospital</span> Hospital in Ottawa, Ontario

The Ottawa Hospital's General Campus is one of three main campuses of The Ottawa Hospital in Ottawa, Ontario, Canada. With 569 beds, the General Campus includes The Ottawa Hospital Rehabilitation Centre and the Cancer Centre.

Stem-cell therapy uses stem cells to treat or prevent a disease or condition. As of 2016, the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.

<span class="mw-page-title-main">University of Ottawa Faculty of Medicine</span>

The Faculty of Medicine at the University of Ottawa is a bilingual medical school in Ottawa, Ontario, Canada founded in 1945. It is located at a campus centred on Roger-Guindon Hall in the east end of Ottawa and is attached to the Ottawa Hospital's General Campus. The Health Sciences Complex is separate from the downtown University of Ottawa campus.

<span class="mw-page-title-main">Sinovac Biotech</span> Chinese biopharmaceutical company

Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China.

Gustav Gaudernack is a scientist working in the development of cancer vaccines and cancer immunotherapy. He has developed various strategies in immunological treatment of cancer. He is involved in several ongoing cellular and immuno-gene therapeutic clinical trials and his research group has put major efforts into the development of various T cell-based immunotherapeutic strategies.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

<span class="mw-page-title-main">Derrick Rossi</span> Canadian stem cell biologist

Derrick J. Rossi, is a Canadian stem cell biologist and entrepreneur. He is a co-founder of the pharmaceutical company Moderna.

Hans Keirstead is a medical scientist and entrepreneur specializing in stem cell research.

Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

<span class="mw-page-title-main">Convidecia</span> Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

<span class="mw-page-title-main">Covaxin</span> Vaccine against COVID-19

Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwatersrand.

<span class="mw-page-title-main">Sinopharm WIBP COVID-19 vaccine</span> Vaccine against COVID-19

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

Peter Jüni is a Swiss physician, general internist, and epidemiologist based in England.

Peter Andrew McCullough is an American cardiologist. He was vice chief of internal medicine at Baylor University Medical Center and a professor at Texas A&M University. During the COVID-19 pandemic, McCullough promoted misinformation about COVID-19, its treatments, and mRNA vaccines.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

BIOTECanada, or the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

References

  1. ↑ Ottawa Hospital Research Institute (April 22, 2009). "Ottawa Health Research Institute changes name to Ottawa Hospital Research Institute" . Retrieved June 5, 2014.
  2. 1 2 "Ottawa Hospital Research Institute". www.ohri.ca. Retrieved 2022-11-02.
  3. ↑ "Our People". Ottawa Hospital Research Institute. Archived from the original on 2013-07-02.
  4. ↑ "Research Programs". Ottawa Hospital Research Institute.
  5. ↑ "Dr. Ronald Worton, Founding CEO of the Ottawa Hospital Research Institute, to be inducted into the Canadian Medical Hall of Fame". Ottawa Hospital Research Institute. September 24, 2013.
  6. ↑ "Dr. Duncan Stewart, science director at the Ottawa Hospital Research Institute, has been named to head up the Canadian Vascular Network". Ottawa Citizen. February 23, 2014. Archived from the original on June 9, 2014.
  7. ↑ "Ottawa Health Research Institute holds Annual General Meeting and welcomes new CEO". Ottawa Hospital Research Institute. September 24, 2007.
  8. ↑ Department of Biochemistry, Microbiology and Immunology (2021-12-13). "Made-in-Ottawa vaccine could help in global fight against COVID-19, including new variants". University of Ottawa . Archived from the original on 2023-03-19. Retrieved 2023-03-19.
  9. ↑ Rudnicki, Jonathan (2021-12-30). "Scientific team behind Ottawa-made COVID-19 vaccine aims to support long-term global response to pandemic". Capital Current. Archived from the original on 2023-03-19. Retrieved 2023-03-19.
  10. ↑ Boulton, Stephen; Poutou, Joanna; Martin, Nikolas T.; Azad, Taha; Singaravelu, Ragunath; Crupi, Mathieu J. F.; Jamieson, Taylor; He, Xiaohong; Marius, Ricardo; Petryk, Julia; Souza, Christiano Tanese de; Austin, Bradley; Taha, Zaid; Whelan, Jack; Khan, Sarwat T. (2022-05-04). "Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection". Molecular Therapy. 30 (5): 1885–1896. doi:10.1016/j.ymthe.2021.10.008. ISSN   1525-0016. PMC   8527104 . PMID   34687845.
  11. ↑ Duffy, Andrew (2021-12-16). ""Versatile" made-in-Ottawa COVID-19 vaccine ready for human trials". Ottawa Citizen . Archived from the original on 2021-12-18. Retrieved 2023-03-19.
  12. ↑ Atkins, Harold L.; Bowman, Marjorie; Allan, David; Anstee, Grizel; Arnold, Douglas L.; Bar-Or, Amit; Bence-Bruckler, Isabelle; Birch, Paul; Bredeson, Christopher; Chen, Jacqueline; Fergusson, Dean; Halpenny, Mike; Hamelin, Linda; Huebsch, Lothar; Hutton, Brian (2016-08-06). "Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial". The Lancet. 388 (10044): 576–585. doi:10.1016/S0140-6736(16)30169-6. ISSN   0140-6736. PMID   27291994. S2CID   4530484.
  13. ↑ Kuang, Shihuan; Kuroda, Kazuki; Le Grand, Fabien; Rudnicki, Michael A. (2007-06-01). "Asymmetric self-renewal and commitment of satellite stem cells in muscle". Cell. 129 (5): 999–1010. doi:10.1016/j.cell.2007.03.044. ISSN   0092-8674. PMC   2718740 . PMID   17540178.
  14. ↑ "Project Big Life". www.projectbiglife.ca.
  15. ↑ Breitbach, Caroline J.; Burke, James; Jonker, Derek; Stephenson, Joe; Haas, Andrew R.; Chow, Laura Q. M.; Nieva, Jorge; Hwang, Tae-Ho; Moon, Anne; Patt, Richard; Pelusio, Adina; Le Boeuf, Fabrice; Burns, Joe; Evgin, Laura; De Silva, Naomi (2011-08-31). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans". Nature. 477 (7362): 99–102. doi:10.1038/nature10358. ISSN   1476-4687. PMID   21886163. S2CID   4365604.
  16. ↑ Fergusson, Dean A.; Hébert, Paul C.; Mazer, C. David; Fremes, Stephen; MacAdams, Charles; Murkin, John M.; Teoh, Kevin; Duke, Peter C.; Arellano, Ramiro; Blajchman, Morris A.; Bussières, Jean S.; Côté, Dany; Karski, Jacek; Martineau, Raymond; Robblee, James A. (2008-05-29). "A comparison of aprotinin and lysine analogues in high-risk cardiac surgery". The New England Journal of Medicine. 358 (22): 2319–2331. doi: 10.1056/NEJMoa0802395 . ISSN   1533-4406. PMID   18480196.
  17. ↑ "About Us - Patient Decision Aids - Ottawa Hospital Research Institute". decisionaid.ohri.ca.
  18. ↑ Duffy, Andrew (April 8, 2021). "Treating the untreatable: How and why Canada's CAR-T network was built". Ottawa Citizen.
  19. ↑ "Ottawa Hospital Research Institute". www.ohri.ca.
  20. ↑ "Ottawa Hospital Research Institute". www.ohri.ca.
  21. ↑ "Ottawa Hospital Research Institute". www.ohri.ca.
  22. ↑ "Ottawa Hospital Research Institute". www.ohri.ca.

45°23′35″N75°43′26″W / 45.39307°N 75.72391°W / 45.39307; -75.72391

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.